Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.77 |
| ▸ | PDE1A | P54750 | 3/20 | 0.62 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.62 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.62 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.62 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.62 |
| ▸ | PDE11A | Q9HCR9 | 3/20 | 0.62 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.62 |
| ▸ | PDE2A | O00408 | 1/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | PDE4A | P27815 | 1/20 | 0.59 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9910377 | 1.00 | MET (0.77) | METPDE1APDE4CPDE4DPDE3B | |
| SCHEMBL12049407 | 0.91 | MET (0.67) | METPDE1APDE4CPDE4DPDE3B | |
| SCHEMBL12049406 | 0.90 | MET (0.65) | METPDE1APDE4CPDE4DPDE3B | |
| SCHEMBL14199032 | 0.89 | MET (0.64) | METPDE1APDE4CPDE4DPDE3B | |
| SCHEMBL12049419 | 0.88 | MET (0.64) | METPDE1APDE4CPDE4DPDE3B | |
| SCHEMBL12049408 | 0.88 | MET (0.61) | METPDE1APDE4CPDE4DPDE3B | |
| SCHEMBL12049425 | 0.87 | MET (0.61) | METPDE1APDE4CPDE4DPDE3B | |
| SCHEMBL2696561 | 0.87 | MET (1.00) | METPDE1APDE4CPDE4DPDE3B | |
| SCHEMBL2695885 | 0.87 | MET (1.00) | METPDE1APDE4CPDE4DPDE3B | |
| SCHEMBL2699300 | 0.87 | MET (1.00) | METPDE1APDE4CPDE4DPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3093289-A1 | [1,2,4]TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR | Amgen, Inc (US) | 2016-11-16 | — | — | EP | disclosed |
| US-9066954-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9066954-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20130303529-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303529-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-11-14 | — | — | US | disclosed |
| US-8524900-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524900-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2013-09-03 | — | — | US | disclosed |
| EP-2578583-A1 | Fused heterocyclic derivatives and methods of use | Amgen Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| US-8217177-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-8217177-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-8198448-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8198448-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20120107275-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120107275-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090124612-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124612-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | MET 3/4885PDE1A 3611/4885PDE4C 2630/4885 |
| US-20090124612-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | MET 3/4885PDE1A 3611/4885PDE4C 2630/4885 |
| US-20130303529-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | MET 3/4885PDE1A 3611/4885PDE4C 2630/4885 |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | MET 3/4885PDE1A 3611/4885PDE4C 2630/4885 |
| US-20120107275-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | MET 3/4885PDE1A 3611/4885PDE4C 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.